Pfizer’s blockbuster franchises largely met expectations in the quarter. Sales from pneumonia vaccine Prevnar, which is facing new competition from Merck & Co, were US$1.7 billion, edging out estimates of US$1.6 billion. Sales of blood thinner Eliquis were US$2 billion and sales of heart drug Vyndaqel were US$1.7 billion, meeting expectations.
(Feb 3): Pfizer Inc beat fourth-quarter sales estimates on strength from its older drugs as it races to fill gaps from its declining Covid shot and pill franchises.
Pfizer battled to acquire obesity start-up Metsera Inc for as much as US$10 billion ($12.71 billion) late last year in its quest to find new avenues for growth. The drugmaker released data early on Tuesday for one of Metsera’s drugs showing people on the medication lost up to 12.3% of their body weight compared to a placebo at 28 weeks. It’s the first reveal of monthly data for this drug and showed less frequent dosing could be possible.
